Tari A King MD

PubMed

• Impact of pathologic response and individual prognosis after neoadjuvant treatment in patients with early HER2+ and triple-negative breast cancer.
  Chiara Corti, Tianyu Li, Alyssa R Martin, Melissa E Hughes, Tonia Parker
  Breast. 2026-06-01
• ASO Visual Abstract: Receipt of Combined Axillary Dissection and Nodal Irradiation Varies by Age.
  Sara P Myers, Yevgeniya Gokun, Brandon Slover, Ashley P Davenport, Therese Y Andraos
  Annals of Surgical Oncology. 2026-05-25
• Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort.
  Stefania Morganti, Se E Kim, Qingchun Jin, Jaeyoon Cha, Jacqueline E Zeigler
  JNCI Cancer Spectrum. 2026-05-25

Journal Articles

• Molecular Mechanisms Linking High Body Mass Index to Breast Cancer Etiology in Post-Menopausal Breast Tumor and Tumor-Adjacent Tissues  
  Adam M Brufsky, Tari A King, Susan B Brown, Breast Cancer Research and Treatment
• Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma in Situ Following a Core Biopsy Diagnosis of Non-Classic Lobular Carcinoma in Situ  
  Kevin S Hughes, Suzanne B Coopey, Faina Nakhlis, Catherine S Giess, Tari A King, Annals of Surgical Oncology
• Correction to: Margins in Breast-Conserving Surgery After Neoadjuvant Therapy  
  Tari King, Mehra Golshan, Annals of Surgical Oncology

Books/Book Chapters

• Diseases of the Breast 
  Chapter: Lobular Carcinoma In Situ: Biology and Management 
  Page 324 - 336King TA, Reis-Filho JSEditors: Harris JR, Lippman ME, Morrow M, Osborne K.Lippincott, Williams, and Wilkins, Philadelphia, PAEdition 5th,2014
• Current Surgical Therapy 
  Chapter: Cellular, Biochemical and Molecular Targets in Breast Cancer 
  Page 520 - 524King TA, Morrow MEditors: Cameron JL, Cameron AM.Mosby, New York, NYEdition 10th,2010
• Advanced Therapy of Breast Disease 
  Chapter: Management of High Risk Breast Lesions 
  Andrade VP, King TAEditors: Esteva F, Skoracki R and Gildy B.People's Medical Publishing House, CTEdition 3rd,2010

Abstracts/Posters

• Management of the Axilla in Clinical T1-2N0 Patients Undergoing Mastectomy - What Can We Learn from AMAROS?
  Moossdorff M, Nakhlis F, Hu J, Barry W, Losk K, Haskett C, Smidt ML, King TA, Society of Surgical Oncology annual meeting, Seattle, WA, 1/1/2017
• Implementation of Surgeon-Initiated Oncotype DX Ordering Among Breast Cancer Patients to Reduce Chemotherapy Wait Times
  Losk K, Freedman RA, Lin NU, Golshan M, Lester S, Pochebit S, Natsuhara K, Camuso K, King TA, Bunnell CA, American Society of Clinical Oncology Quality Care Symposium, Orlando, FL, 1/1/2017
• Patterns of axillary evaluation in older patients (pts) with breast cancer and impact on adjuvant therapy
  Dominici LS, Sineshaw H, Jemal A, Lin A, King TA, Freedman RA, San Antonio Breast Cancer Symposium, San Antonio, TX, 1/1/2016

Lectures

• RANK-C Attenuates Aggressive Properties of ER-Negative Breast Cancer by Inhibiting NF-κB Activation and EGFR Signaling 
  New York, NY - 10/29/2014
• Changing the Future of Breast Cancer 
  Palm Beach, FL - 1/1/2017
• Lobular Carcinoma in Situ: Risk Factor or Precursor 
  Beth Israel Deaconess Medical Center, Boston, MA - 1/1/2017